U.S. ORTHOPEDIC DEVICE DEVELOPER AND SELLER

NVC2270

About the Company

ExoToe, a U.S.-based Company, developed, obtained federal clearance, commercialized and sells an implant device for surgical use throughout the U.S. The product has been clinically tested, safe and effective alternative to existing surgical interventions. The implant received FDA clearance just before the COVID pandemic, which slowed the Company’s momentum. The device was developed by Drs. Jordan Grossman, Michael Lee, and Shannon Rush, three of the most well-known and respected opinion leaders in foot and ankle surgery. The objective has always been to de-risk the implant for a future owner and not grow the Company. With its evidence-based technology and safe track record, the Company presents a growth opportunity for a new owner.

GROWTH OPPORTUNITIES

  • Increased sales emphasis – The goal was to de-risk, show efficacy and sell to an orthopedic company, not to grow into a standalone business. There is a limited sales team and business is generated through word of mouth or write-ups in medical journals presenting a significant opportunity for growth for a new owner. 
  • Repeat business – The implant has an impressive track record, but little effort has been made to build relationships with surgeons who have successfully employed it. 
  • Scalable Manufacturing – The current manufacturer of record possesses all necessary ISO certifications and offers the scalability required to meet market demands. 
  • Platform Technology – The implant’s current application is for toes but could easily be adapted to hand and other upper extremities. 
INVESTMENT HIGHLIGHTS 
  • Intellectual property – The Company has valuable intellectual property for crimping of fixation for foot bone fractures and fusions. 
  • High success rate – The device has been in the market long enough to show that it works, is safe and effective minimizing risk for a new owner. An independent publication in a peer-review journal demonstrated a best in class fusion rates. 
  • Patient, surgeon satisfaction – The implant’s success rate and ease of use have won over many doctors and patients. 
  • Another option – The implants provide an alternative to other types of devices which have had mixed success.  It is also the revisional implant of choice when primary procedures fail. 
  • Partners in place – The Company has established relationships with capable outside vendors for manufacturing and logistics. It also has a complete DHF (Design History File) and QMS (Quality Management System). 
  • Additional complementary device – The Company is in the process of FDA clearance for a complementary device in the same space creating an additional opportunity for new owners to generate revenue. 
  • Cumulative Devices Implanted – Well over 2,000 

 

REVENUE AND EBITDA

Market Opportunity  Sales Team Projection 
Total annual implant revisions: 30,000 Total sales reps: 200 
Target market share: 30%  Sales per rep per week: 1 unit 
Estimated units: 9,000  Selling weeks per year: 50 (assuming 2 weeks off) 
Revenue per unit: $1,000–$1,200  Total units sold: 200 reps × 1 unit/week × 50 weeks = 10,000 units 
Total potential revenue: $9M–$11M  Projected revenue: $10M–$12M 

 

INTERESTED?

If this opportunity fits your Company, please fill out the below NDA to get started and contacted with more information.

 

Non-Disclosure Agreement

Contact us for more information!

NuVescor Group

(616) 379-4047 Ext: 106